Source comparison
CJC-1295 No DAC Versus Longer-Acting Analogs: Safety Trade-offs
The following table compares CJC-1295 no DAC safety profile against longer-acting GHRH analogs and combination secretagogue protocols. CJC-1295 no DAC ~30 minutes 2-3x daily 20-35% 15-25% Moderate (daily antigen exposure) Best for pulsatile GH research; requir
This comparison does not assign a generated winner or score.
- The following table compares CJC-1295 no DAC safety profile against longer-acting GHRH analogs and combination secretagogue protocols.
- CJC-1295 no DAC
- ~30 minutes
- 2-3x daily
- 20-35%
- 15-25%
- Moderate (daily antigen exposure)
- Best for pulsatile GH research; requires consistent daily administration and rotation protocols to minimize local tissue reactions
- CJC-1295 with DAC
- 5-8 days
- Once weekly
- 10-15%
- 5-10%
- Elevated (ADA documented in 5% at 90 days)
- Extended half-life reduces injection frequency but increases cumulative ADA risk; discontinued from clinical development in 2010 due to safety concerns
- Sermorelin (modified GRF)
- ~10 minutes
- 1-3x daily
- 10-20%
- Low (fewer synthetic modifications)
- Shorter half-life than CJC no DAC; better immunogenicity profile but requires more frequent dosing to maintain plasma levels
- Tesamorelin
- ~45 minutes
- Once daily
- 20-30%
- Low to moderate
- FDA-approved GHRH analog for HIV-associated lipodystrophy; robust safety data over 26 weeks but limited research availability
- Ipamorelin (GHRP-2 analog)
- ~2 hours
- 5-10% (when used alone)
- Low
- Frequently combined with CJC no DAC for synergistic GH release; combination protocols increase GI distress to 25-40% vs monotherapy
- The key distinction in the CJC-1295 no DAC safety profile versus DAC-conjugated versions is administration frequency. Researchers often assume the no-DAC version is safer because it lacks the Drug Affinity Complex modification that prolonged half-life and triggered antibody formation in clinical trials. That assumption is only partially correct. While the no-DAC version avoids the specific immunogenic epitope created by DAC conjugation, it requires 14-21 injections per week versus one injection per week with the DAC version. Dramatically increasing cumulative injection site trauma and local immune activation. By week 10-12, the no-DAC version often produces more frequent injection site reactions than the DAC version despite lower per-dose immunogenicity.
- Combination protocols using CJC-1295 no DAC alongside Ipamorelin or GHRP-2 amplify GH release through complementary receptor pathways but also increase the incidence of GI distress. A 2014 observational study found that GI adverse events occurred in 35-45% of combination-protocol administrations versus 20-30% for CJC no DAC monotherapy. The mechanism is additive: GHRH agonists delay gastric emptying, while GHRPs stimulate ghrelin receptor activation in the stomach and intestines, compounding motility effects.